Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov;26(6):1061-1063.
doi: 10.1007/s40257-025-00982-4. Epub 2025 Sep 1.

Exploring Suzetrigine's Role in Dermatologic Surgery: A Novel Nonopioid Analgesic for Postoperative Pain Management

William J Nahm  1   2 , Sameer G Gupta  3 , Ryan Chen  4   5 , Vinod E Nambudiri  5   6
Affiliations
Editorial

Exploring Suzetrigine's Role in Dermatologic Surgery: A Novel Nonopioid Analgesic for Postoperative Pain Management

William J Nahm et al. Am J Clin Dermatol. 2025 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of Interest: None declared. Ethics Approval: Not applicable. Patient Consent: Not applicable. Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request. Code Availability: Not applicable Reprint Requests: William J. Nahm. Author Contributions: William Nahm: conceptualization, material preparation, writing—original and final draft preparation. Sameer G. Gupta: conceptualization, material preparation, writing—original draft preparation, supervision. Ryan Chen: material preparation and writing—original draft presentation; Vinod Nambudiri: conceptualization, material preparation, writing—original draft preparation, supervision.

References

    1. Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, et al. Pharmacology and mechanism of action of Suzetrigine, a potent and selective Na(V)1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025;14(2):655–74. https://doi.org/10.1007/s40122-024-00697-0 . - DOI - PubMed - PMC
    1. McLawhorn JM, Stephany MP, Bruhn WE, Crow LD, Coldiron BM, Hruza GJ, et al. An expert panel consensus on opioid-prescribing guidelines for dermatologic procedures. J Am Acad Dermatol. 2020;82(3):700–8. - DOI - PubMed
    1. Veerabagu SA, Cheng B, Wang S, Etzkorn JR, Kilaru AS, Noe MH, et al. Rates of opioid prescriptions obtained after Mohs surgery: a claims database analysis from 2009 to 2020. JAMA Dermatol. 2021;157(11):1299–305. https://doi.org/10.1001/jamadermatol.2021.3468 . - DOI - PubMed
    1. Rind DM, McQueen B, Nikitin D, Lee W, DiStefano MJ, Raymond F, et al. Suzetrigine for acute pain: effectiveness and value. INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW; 2024.
    1. Bertoch T, D’Aunno D, McCoun J, Solanki D, Taber L, Urban J, et al. Suzetrigine, a nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025;142(6):1085–99. https://doi.org/10.1097/aln.0000000000005460 . - DOI - PubMed

Publication types

LinkOut - more resources